Lupo di mare
12 Mar 2018
Generic delay "Vectura was down 4.4% on news it, along with partner Hikma Pharmaceuticals, will be required to conduct an additional clinical endpoint study for the development of a generic to GlaxoSmithKline's Advair Diskus."
Yee Wo
04 Mar 2018
Re: Discussion board The Lemon Fool is where many of us also blog. Massive advantage being is it's not affiliated to any financial services company and is run on a non-commercial basis........
sound money
25 Feb 2018
Discussion board With the migration to a new ii site of which along with others I will continue to support, thought you might like to consider also trying the discussion board on[link] will find some familiar posters including Soi, Magoo, Jack Dawson, Vtec, Damp Seaweed, SBK etc.It's a good natured board which covers the whole investment spectrum. If you enjoy discussions without acrimony you would be most welcome.Just follow the link.M
sound money
20 Feb 2018
Recent Results Below are some comments from Sharecast regarding recent results"GlaxoSmithKline, reaffirmed its dividend for this 2018 earlier this month, saying that safeguarding shareholder returns was a higher priority than large-scale mergers and acquisitions.Unveiling her first full-year results since taking over as chief executive, Walmsley said she was "increasingly confident" that GSK's new suite of products would help it deliver "mid- to high single-digit growth" in the years leading to 2020."This would suggest nothing ras on the takeover front. Emma seems to have her fingers on the pulse.M
Lupo di mare
17 Feb 2018
Re: Pfizer auction - FURTHER Nice of you to highlight it, Bill. I tend not to go into too much detail, except, as Sound has highlighted, where MRO is bidding for GKN, and boy am I incensed about that proposed carve up.Nowt wrong with creating wealth but not at the expense of a great company.
sound money
17 Feb 2018
Re: Pfizer auction - FURTHER It certainly was a good call.Lupo's certainly worth listening to. Not on the GKN board though.😉M
Bill1703
17 Feb 2018
Re: Pfizer auction - FURTHER "Why the exclamation mark, Bill?"Just acknowledging the wisdom of your earlier $10bn call - worth highlighting!
Lupo di mare
17 Feb 2018
Re: Pfizer auction - FURTHER Why the exclamation mark, Bill? Lupo!
Bill1703
17 Feb 2018
Re: Pfizer auction - FURTHER I found an interesting piece in the NY Times, from back in October... full text copied below. Two interesting takeaways for me
1) Using similar (admittedly, broad) assumptions to my own earlier analysis, it suggests a value of $10bn for the business - this was obviously before we started seeing talk of higher prices (ie. $14/15bn, up to $20bn), begging the question of the original source for these higher figures! (2) The idea that Pfizer could fold the biz into the existing GSK/Novartis JV, becoming a possible third (and minority) partner in the shared business.IMHO I agree that $10bn (as per Lupo!) looks about the right value, on a stand-alone basis. The likes of GSK etc, with already-substantial Consumer interests, would be able to justify paying more (and Pfizer would expect them to) given substantial synergies in a market which is all about scale, as the article suggests. But obviously, the more you "pay away" these synergies up front, the less reason to do the deal.But I like the latter idea... bringing Pfizer into the JV structure (with or without buying Novartis out first) would not only spread the risk and minimise the capital commitment, but it would likely pave the way for less of a premium in the price, with Pfizer retaining a share of upside from both achieved synergies and possible future growth. No idea how much this might appeal to Pfizer, I am sure they'd prefer a clean exit at a good price - but it might be the best deal they can get... ********** **** "Painkillers and hemorrhoid cream: These are either the recipe for a terrible night in, or a potentially good corporate deal. Pfizer, the $215 billion United States drug maker, has assigned investment banks to look into a spin off or sale of its consumer-goods division, which makes Advil and Preparation H. GlaxoSmithKline’s new boss, Emma Walmsley, would be well placed to offer them a home.Over-the-counter products are a tiny sideline for Pfizer, accounting for just 6.4 percent of its revenue last year. Ian Read, Pfizer’s chief executive, therefore loses little from putting the business on the block. While these goods might share manufacturing and shipping processes with prescription medicines, the unique nature of cooking up, testing and distributing drugs to patients suggests there is not much reason to keep them together. Germany-based Merck is considering a similar split.Of course, some are less dismissive – including Ms. Walmsley. She took over as chief executive in April after having run the consumer-goods joint venture Glaxo co-owns with Switzerland-based Novartis. Ms. Walmsley has pledged to focus on Glaxo’s drugs, like its H.I.V. and asthma meds, rather than her old division, which makes just 15 percent of group operating profit. But as she will know, consumer goods are a game of scale — something rivals like Sanofi, Reckitt Benckiser and Johnson & Johnson also covet.A neat solution would be to fold Pfizer’s consumer business into the Glaxo-Novartis joint venture. Valued at 15 times operating profit — roughly the 10-year average for the consumer-staples sector — the business could be worth $10 billion. That assumes Pfizer’s consumer operating margin is roughly the same 20 percent that Glaxo is targeting. Since Glaxo now values its venture with Novartis at $27 billion, Pfizer could argue for a stake somewhere south of 30 percent. One day, the enlarged company might make for a more lucrative spin off or sale than Pfizer could muster today.Timing matters. Mr. Read said he will make a decision sometime in 2018. Ideally, Glaxo would buy Novartis out before doing any other deals, since it would otherwise have to pay the Swiss company for its share of any synergies that came from adding Pfizer. Besides, Ms. Walmsley has only been in the job for six months. Nonetheless, she could do worse than toss an offer over Pfizer’s counter."
picstloup
16 Feb 2018
Re: Topped up Me too. Stuck myself down for another 762 of these at £13.11.55 at 14.04.Should have topsliced at £17 but didn't. 14% up on my original stake 5+ years ago, hardly stellar, but decent income and decent prospects for growth.
Lupo di mare
16 Feb 2018
Re: Any chartists I should have added that this sp looks like a buying opportunity.
Lupo di mare
15 Feb 2018
Any chartists out there?I'm no chartist, although I might become one . From a simple chartist's point of view, the 3-year chart looks like an old-fashioned (like me) 'W' formation. Don't any long-term holder compare GSK to the ftse 100 over the same period - it would only make you sad.
Lupo di mare
14 Feb 2018
Trelegy Ellipta LONDON (Alliance News) - Pharmaceutical firm GlaxoSmithKline PLC announced Wednesday it has submitted IMPACT study data to the European Medicines Agency for an expanded label for its Trelegy Ellipta treatment for lung disease.The submission, the FTSE 100-listed company said, is based on data showing Trelegy Ellipta was superior to a number of other treatments for chronic obstructive pulmonary disease on endpoints such as reduced flare-ups, improved lung functions, and health-related quality of life.Trelegy Ellipta is a once daily, single inhaler triple therapy containing fluticasone furoate, umeclidinium, and vilanterol. Glaxo said approval would mean physicians could use it to treat a wider number of patients at risk of exacerbations in COPD symptoms.It was approved in Europe in November as a maintenance treatment for adults with COPD, and Glaxo also has submitted a new drug application to the US Food & Drug Administration which is currently being reviewed.Head of Respiratory Therapy Area Dave Allen said: "This filing is primarily based on the IMPACT study, which clarifies the type of patient most likely to benefit from once-daily single inhaler triple therapy, and adds to the evidence supporting the clinical profile of Trelegy Ellipta."The submission reflects our confidence in this medicine, which we believe has the potential to be an effective treatment option for appropriate patients with COPD who require triple therapy for symptom relief and exacerbation reduction."
Lupo di mare
13 Feb 2018
Re: Pfizer Consumer Healthcare auction Bill - "See the NG board today for a slightly more detailed view,"Thanks, Bill, trust me that I have a more detailed view myself, as do most.
Lupo di mare
12 Feb 2018
Re: Pfizer Consumer Healthcare auction Bill - "Bought a reasonable sized slug this morning - my first time on the GSK register"What made you do the right thing, I wonder.It's Nr.2 in my portfolio, just behind RDSB, and followed by:-MYIULVRHFD HSBAGKN and I won't bore you further.I'm somewhat concerned about my holdings in utilities, especially after John McMao's comments, and JC's, at the weekend. They say that investors will be given (ta everso) bonds in return for their shares. They'd have to get that legislation through for the grand theft to succeed, and unless they get a big majority (if elected) that would not be a given; so I'll keep taking the divis, thanks.
